Promoter holding
64.27%
DL
Dr.Reddy'S Laboratories Ltd - Due diligence report
A 360° intelligence report on Dr. Reddy'S: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Dr. Reddy'S — 360° Intelligence Report
Generated from MCA filings & public records72/100
Trust Score
Moderate
Dr. Reddy'S is assessed as Moderate with a Trust Score of 72/100. Dr. Reddy'S is an active public limited indian non-government company incorporated in 1984, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Dr.Reddy'S Laboratories Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AA+).
Charges position: 17 open (34.23 cr) · 78 satisfied (586.71 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Canara Bank | 28 | 48.0 cr |
| The Industrial Credit & Investment Corp. Of India Ltd | 14 | 48.0 cr |
| Export Import Bank Of India | 4 | 48.0 cr |
| Globaltrust Bank Ltd | 2 | 48.0 cr |
| State Bnak Of India | 2 | 48.0 cr |
| Anz Grindlays Bank | 5 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: EPFO.
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (96 disclosure(s)).
- 24 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| KODUMUDI PRANATHARTHIHARAN KRISHNAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| LEO PURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| EREZ ISRAELI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN MADHAVAN KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SATISH REDDY KALLAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATESWARA PRASAD GUNUPATI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALPNA HANSRAJ SETH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CLAUDIO DR. ALBRECHT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PENNY CHAN WAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHIKHA SANJAYA SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Kumar Randhir Singh | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJIV SOSHIL MEHTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Mannam Venkata Narasimham | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- No disqualified or deactivated DINs.
- 3 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
6
Group entities
7
Capital events
110 allotment(s) · 8 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Aurigene Discovery Technologies (malaysia) Sdn. Bhd. | Subsidiary Company | 74.00% |
| Aurigene Discovery Technologies Limited | Subsidiary Company | 74.00% |
| Aurigene Pharmaceutical Services Limited | Subsidiary Company | 74.00% |
| Beta Institut Gemeinntzige Gmbh | Subsidiary Company | 74.00% |
| Betapharm Arzneimittel Gmbh | Subsidiary Company | 74.00% |
| Cheminor Investments Limited | Subsidiary Company | 74.00% |
| Chirotech Technology Limited | Subsidiary Company | 74.00% |
| Dr Reddys Laboratories Kazakhstan Llp | Subsidiary Company | 74.00% |
| Dr. Reddy's (beijing) Pharmaceutical Co. Limited | Subsidiary Company | 74.00% |
| Dr. Reddy's Laboratories (thailand) Limited | Subsidiary Company | 74.00% |
Key managerial personnel: EREZ ISRAELI (CEO) · SATISH REDDY KALLAM (Whole-time director) · VENKATESWARA PRASAD GUNUPATI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 45 · Distress 75
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 42+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (42/100).
17 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 3.09 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence61/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment77/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 17 open charge(s) of 34.23 cr already registered.
- Compliance gaps should be priced into terms.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events24 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Aug 2024
Director appointed
Mannam Venkata Narasimham (Cfo)
13 Feb 2024
Director ceased
SANJIV SOSHIL MEHTA
29 Dec 2023
Director appointed
SANJIV SOSHIL MEHTA (Director)
14 Nov 2023
Director ceased
ALPNA HANSRAJ SETH
19 Sep 2023
Director appointed
ALPNA HANSRAJ SETH (Director)
26 Jul 2023
Director ceased
CLAUDIO DR. ALBRECHT
10 May 2023
Director appointed
CLAUDIO DR. ALBRECHT (Director)
16 Dec 2022
Securities allotted
7436 Equity Shares - 37,180.00 raised
Securities allotted
13485 Equity Shares - 67,425.00 raised
Securities allotted
2025 Equity Shares - 52.79 Lakh raised
Securities allotted
580 Equity Shares - 21.34 Lakh raised
27 Oct 2022
Securities allotted
885 Equity Shares - 4,425.00 raised
Securities allotted
1830 Equity Shares - 9,150.00 raised
10
Key Observations
Auto-generated from the data aboveRevenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
13 active director(s) / partner(s); board looks stable and experienced.
24 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 6 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA+ from Indiarating.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 110 security allotment(s) - amounts available in the full report.
57 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Ind Swift | L24232CH1995PLC015553 | Chandigarh, Chandigarh, India |
| Satish Sugars Limited | U46620KA2000PLC026920 | Gokak Taluk, Karnataka, India |
| Ghcl | L24100GJ1983PLC006513 | Ahmedabad, Gujarat, India |
| Dow Agrosciences | U01110TG1994PTC151731 | Hyderabad, Telangana, India |
| Coronaremedies | L24231GJ2004PLC044656 | Daskroi, Gujarat, India |
| Solara | L24230MH2017PLC291636 | Thane, Maharashtra, India |
| Indigo Paints | L24114PN2000PLC014669 | Pune, Maharashtra, India |
| Balaji Speciality Chemicals | L24132MH1988PLC049387 | Solapur, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Dr. Reddy'S before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Dr. Reddy'S: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Dr. Reddy'S - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Dr. Reddy'S pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Dr. Reddy'S - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Dr. Reddy'S an active company?
Dr. Reddy'S has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Dr. Reddy'S financially healthy?
Dr. Reddy'S has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Dr. Reddy'S?
Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Dr. Reddy'S?
Promoters hold a majority stake - exact percentages are in the full report. 13 active director(s) are on record.
Does Dr. Reddy'S have loans or charges against its assets?
17 open charge(s) are registered against its assets, and 78 earlier charge(s) stand satisfied.
Is Dr. Reddy'S up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Dr. Reddy'S?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
